True Leaf Medicine International Inc.
True Leaf Medicine International Inc.
- ISIN: CA89785C1077
- Land: .
Nachricht vom 16.03.2017 | 08:05
True Leaf Signs 'Gold-standard' Agency to Represent Product Line to National Pet Chains
DGAP-News: True Leaf Medicine International Inc. / Key word(s): Miscellaneous
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2017) - True Leaf Pet Inc., wholly owned subsidiary of True Leaf International Ltd. (CSE: MJ) (FSE: TLA) has signed an agreement with Chuck Latham Associates (CLA) that will see the firm represent the innovative True Hemp™ product line to major national and online pet retailers like Petco®, PetSmart™, Pet Supplies Plus®, and Amazon.
CLA is known as 'The Pet Channel Expert' with four strategically located offices and over 800 company associates working across the USA. CLA is the leading firm in the pet specialty market that provides national coverage across all major sales channels, including independent pet stores, farm stores, national pet retailers, and Internet retailers.
'This is a significant milestone for us,' said True Leaf CEO Darcy Bomford. 'CLA is the gold-standard rep-firm in the pet industry and we're happy to have their team represent our line across the US.' True Leaf Pet signed on after discussions with CLA earlier this year and is now in the on-boarding process with the firm as it moves into the busy spring season.
CLA Executive Bob Haege says True Leaf was a great fit 'because they have an innovative product line that meets US regulatory criteria, led by a great team with vast industry experience. We see True Hemp™ as a growth engine for stores looking for a legal & effective product line for hemp-friendly consumers, especially the valuable millennial demographic. '
True Leaf Pet is now preparing for the busy trade show season and putting together the finishing touches on a newly expanded product line that will be on display at the upcoming Global Pet Expo March 22-24 in Orlando Florida. 'We have meetings set with the CLA team and prospective customers at the show and look forward to a great response to our new products,' says True Leaf Pet CEO Darcy Bomford.
About True Leaf
True Leaf Medicine International Ltd., through its wholly-owned subsidiary 'True Leaf Pet', has entered the $104.9 billion global pet care industry with a line of hemp-focused pet chews and supplements marketed through natural pet health and veterinary channels in Europe, Canada, and the United States. The company has also filed an application under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR) to become a Canadian licensed producer through its 'True Leaf Medicine' subsidiary. It has passed through the preliminary and enhanced screening process of Health Canada's review and is currently awaiting security clearance and 'pre-licensing inspection' approval.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS PRESS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words 'anticipate', 'continue', 'estimate', 'expect', 'may', 'will', 'project', 'should', 'believe' and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks discussed in the Company's continuous disclosure filings available under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.
Click on, or paste the following link into your web browser, to view the associated documents http://www.newsfilecorp.com/release/25675
|Company:||True Leaf Medicine International Inc.|
|End of News||DGAP News Service|
GBC im Fokus
Neovacs S.A.: Kursziel auf 3,30 € angehoben
In den letzten Monaten hatte die Neovacs S.A. einen positiven Newsflow. Im Vordergrund steht die Vertriebspartnerschaft für den chinesischen Markt, wodurch sich bis nach dem ersten Vermarktungsjahr Gesamterträge von bis zu 65 Mio. € ergeben können. Zudem verläuft der klinische Zulassungsprozess des IFNα-Kinoid zur Behandlung von SLE (Systemischer Lupus) und Dermatomyositis planmäßig. Wir haben in unsere Bewertung aktualisiert und ein Kursziel von 3,30 € je Aktie (bisher: 2,90 €) ermittelt. Das Rating lautet weiter KAUFEN.
Der AKTIONÄR News
30. April 08:28 Linde: Was für eine Woche!
28. April 15:56 Zahlen und Zukäufe: Aves One bleibt auf Turnaround-Kurs
28. April 14:49 Nintendo: Switch sei Dank – neue Produkte sorgen für Schwung
28. April 14:24 Bayer und Medigene – 2 gesunde Aktien für jedes Depot
28. April 12:34 Goldexperte Bußler: Die Korrektur zeigt ihr grausiges Gesicht
News im Fokus
Erfolgreicher Start in das neue Geschäftsjahr für Continental
28. April 2017, 08:29
Q1 Results 2017
10. Mai 2017
Original-Research: Nemetschek SE (von Montega AG): Kaufen
28. April 2017